Obesity Pandemic
TABLE OF CONTENTS
Volume 81, Issue 5 (May 2007)
Editorial |
News and Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
Contents
Contents
In this issue FREE
Clin Pharmacol Ther 81: 613; doi:10.1038/sj.clpt.6100197
See also: State of the Art by CefaluSee also: Practice by Herman et al. See also: Ethics by SkylerSee also: Public Policy by Hill et al. See also: Education by Jones et al.Editorial
Innovation and Improvement in the Treatment of Obesity and Diabetes
S W Ryder
Clin Pharmacol Ther 81: 615-619; doi:10.1038/sj.clpt.6100189
News and Views
Highlights
Highlights
Clin Pharmacol Ther 81: 620-621; doi:10.1038/sj.clpt.6100207
ASCPT News
ASCPT News
Clin Pharmacol Ther 81: 622-623; doi:10.1038/sj.clpt.6100203
Macroscopy
Is the Dx for Welfare Rx?
M H T Ridinger
Clin Pharmacol Ther 81: 624-626; doi:10.1038/sj.clpt.6100196
Perspectives
Point/Counterpoint
Aggressive Management of Obesity in Children and Young Adults: The Known Challenges and Potential Opportunities FREE
P J Barter and C L Shear
Clin Pharmacol Ther 81: 627-630; doi:10.1038/sj.clpt.6100162
Commentaries
Grapefruit Juice, a Glass Full of Drug Interactions?
B J Kirby and J D Unadkat
Clin Pharmacol Ther 81: 631-633; doi:10.1038/sj.clpt.6100185
Letter to the Editor
Glutathione-S-Transferase (GST) M1 Null Genotype and Combined GSTM1 and GSTT1 Null Genotypes as a Risk Factor for Alcoholic Mild Liver Dysfunction
K Oniki, K Ueda, M Hori, S Mihara, T Marubayashi and K Nakagawa
Clin Pharmacol Ther 81: 634-635; doi:10.1038/sj.clpt.6100123
State of the Art
State of the Art
Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents FREE
W T Cefalu
Clin Pharmacol Ther 81: 636-649; doi:10.1038/sj.clpt.6100156
Research
Communication
Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High-Dose Simvastatin
B A Schick, R Laaksonen, J J Frohlich, H Päivä, T Lehtimäki, K H Humphries and H C F Côté
Clin Pharmacol Ther 81: 650-653; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100124
Reports
Evidence for Coexistence of Three 
-Adrenoceptor Subtypes in Human Peripheral Lymphocytes
Xi-Yong Yu, Shu-Guang Lin, Xiao-Mei Wang, Yuan Liu, Bin Zhang, Qiu-Xiong Lin, Min Yang and Shu-Feng Zhou
Clin Pharmacol Ther 81: 654-658; advance online publication, March 14, 2007; doi:10.1038/sj.clpt.6100154
Articles
Plasma and Tissue Pharmacokinetics of Epirubicin and Paclitaxel in Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Primary Breast Cancer
M Hunz, A Jetter, M Warm, E Pantke, M Tuscher, G Hempel, U Jaehde, M Untch, C Kurbacher and U Fuhr
Clin Pharmacol Ther 81: 659-668; advance online publication, February 14, 2007; doi:10.1038/sj.clpt.6100067
Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol
U I Schwarz, H Hanso, R Oertel, S Miehlke, E Kuhlisch, H Glaeser, M Hitzl, G K Dresser, R B Kim and W Kirch
Clin Pharmacol Ther 81: 669-678; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100191
Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics
L Becquemont, M Neuvonen, C Verstuyft, P Jaillon, A Letierce, P J Neuvonen and C Funck-Brentano
Clin Pharmacol Ther 81: 679-684; advance online publication, February 14, 2007; doi:10.1038/sj.clpt.6100098
Prenatal Multivitamin Supplementation and Rates of Pediatric Cancers: A Meta-Analysis FREE
Y I Goh, E Bollano, T R Einarson and G Koren
Clin Pharmacol Ther 81: 685-691; advance online publication, February 21, 2007; doi:10.1038/sj.clpt.6100100
A Genetic Variation in the Adenosine A2A Receptor Gene (ADORA2A) Contributes to Individual Sensitivity to Caffeine Effects on Sleep
J V Rétey, M Adam, R Khatami, U F O Luhmann, H H Jung, W Berger and H-P Landolt
Clin Pharmacol Ther 81: 692-698; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100102
Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects
J Brockmöller, I Meineke and J Kirchheiner
Clin Pharmacol Ther 81: 699-707; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100116
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir
F Josephson, A Allqvist, M Janabi, J Sayi, E Aklillu, M Jande, M Mahindi, J Burhenne, Y Bottiger, L L Gustafsson, W E Haefeli and L Bertilsson
Clin Pharmacol Ther 81: 708-712; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100117
PPARG Locus Haplotype Variation and Exacerbations in Asthma
C N A Palmer, A S F Doney, T Ismail, S P Lee, I Murrie, D F Macgregor and S Mukhopadhyay
Clin Pharmacol Ther 81: 713-718; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100119
Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers
C B Eap, S Crettol, J-S Rougier, J Schläpfer, L Sintra Grilo, J-J Déglon, J Besson, M Croquette-Krokar, P-A Carrupt and H Abriel
Clin Pharmacol Ther 81: 719-728; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100120
Using HapMap Tools in Pharmacogenomic Discovery: The Thiopurine Methyltransferase Polymorphism
T S Jones, W Yang, W E Evans and M V Relling
Clin Pharmacol Ther 81: 729-734; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100135
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
N A Farid, C D Payne, D S Small, K J Winters, C S Ernest II, J T Brandt, C Darstein, J A Jakubowski and D E Salazar
Clin Pharmacol Ther 81: 735-741; advance online publication, March 14, 2007; doi:10.1038/sj.clpt.6100139
Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians
H Schelleman, Z Chen, C Kealey, A S Whitehead, J Christie, M Price, C M Brensinger, C W Newcomb, C F Thorn, F F Samaha and S E Kimmel
Clin Pharmacol Ther 81: 742-747; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100144
Discovery & Development
Discovery
New Targets for Obesity Pharmacotherapy
L J Aronne and Z D Thornton-Jones
Clin Pharmacol Ther 81: 748-752; doi:10.1038/sj.clpt.6100163
Development
Challenges in the Discovery and Development of New Agents for the Treatment of Obesity
M A Staten
Clin Pharmacol Ther 81: 753-755; advance online publication, March 21, 2007; doi:10.1038/sj.clpt.6100161
Obesity Pharmacotherapy from a Regulatory Perspective: Overview and Key Challenges
N I Hutchinson and S W Ryder
Clin Pharmacol Ther 81: 756-760; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100169
Regulation & Use
Practice
Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin FREE
G A Herman, P P Stein, N A Thornberry and J A Wagner
Clin Pharmacol Ther 81: 761-767; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100167
Ethics
Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects FREE
J S Skyler
Clin Pharmacol Ther 81: 768-771; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100179
Public Policy
The Role of Public Policy in Treating the Epidemic of Global Obesity
J O Hill, J C Peters and H R Wyatt
Clin Pharmacol Ther 81: 772-775; advance online publication, February 21, 2007; doi:10.1038/sj.clpt.6100107
